Anthra valrubicin
Executive Summary
NDA 20-892 for AD-32 (valrubicin) for refractory carcinoma in situ of the urinary bladder will be discussed by FDA's Oncologic Drugs Advisory Committee at its June 1 meeting. In the afternoon, the committee will consider Rhone-Poulenc Rorer's Taxotere (docetaxel) supplemental NDA (20-449/S-005) for locally advanced or metastatic breast cancer after failure of previous chemotherapy. The meeting begins at 8:30 a.m. at the Gaithersburg, Md. Hilton..